BMRN

BioMarin PharmaceuticalA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$86.00

Analysis reference price unavailable

Analysis 2026-09-02 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$73.00

Analysis reference price unavailable

Analysis 2026-09-02 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$54.00

Analysis reference price unavailable

Analysis 2026-09-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-02

AI commentary

News tone is constructive after the Q2 beat, raised guidance, and portfolio expansion. The SEC earnings release provides strong primary-source support [#SEC-8K-2026-08-06]; a stored secondary recap also reports a $989.7 million quarter and positive share reaction [#PR-EARNINGS-2026-08-20]. Social, options, short-interest, and employee-sentiment data are unavailable; zero placeholders should not be interpreted as positive signals. The setup supports cautious monitoring rather than a high-conviction upgrade.

RankAlpha Sentiment Codex - 2026-09-02

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-06eventQ2 2026 beat and raised FY26 guidanceMedium impact

BioMarin reported Q2 revenue of approximately $990 million, up 20% year over year, and increased full-year 2026 revenue, VOXZOGO revenue, and non-GAAP EPS guidance [#SEC-8K-2026-08-06]. The catalyst is supportive but largely reflected in the post-earnings move.

2026-09-30eventVOXZOGO hypochondroplasia regulatory and data milestonesHigh impact

BioMarin submitted an sNDA for VOXZOGO in hypochondroplasia following positive Phase 3 CANOPY-HCH-3 results. The full dataset is expected at a September medical meeting, with an application-status update planned alongside Q3 earnings [#SEC-8K-2026-08-06].

2027-12-31catalystAmicus portfolio integration and synergy realizationHigh impact

Integration of GALAFOLD and POMBILITI plus OPFOLDA expands BioMarin’s commercial portfolio. Management expects the combination and cost synergies to support revenue growth, margin expansion, and operating cash flow through the mid-2030s [#SEC-8K-2026-08-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-02 • Updated nightlySource: Internal modelMethodology